DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that enrollment in its Phase 2/3 ReMEDy2 trial has reached 75% of the 200-patient ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE